BofA analyst Michael Ryskin lowered the firm's price target on NeoGenomics to $11 from $13 and keeps a Neutral rating on the shares. 1 results were "modestly positive, though unlikely to materially change the broader debate," says the analyst, who updated the firm's model for the results.
